Abstract
Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Current Pharmaceutical Design
Title:Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies
Volume: 18 Issue: 37
Author(s): Adam Reich and Jacek C. Szepietowski
Affiliation:
Keywords: Anti-pruritic agents, itch, opioids, peripheral opioid system, skin, analgesia, pruritus, μ-opioid receptors (MOR), keratinocytes, anti-inflammatory drugs.
Abstract: Administration of opioids for analgesia may produce pruritus. It was believed, that this effect is mediated centrally by activation of μ-opioid receptors (MOR). However, recent data suggested that opioids may also mediate pruritus directly in the skin. A number of skin cell types, including keratinocytes, dermal mast cells, fibroblasts or macrophages, were shown to express both MOR as well as other opioid receptors. It was demonstrated, that the activation of MOR in the skin elicited pruritus, while activation of cutaneous µ- opioid receptors had anti-pruritic effect. Moreover, activation of opioid receptors in the skin modulated not only pruritus, but also inflammatory response. Taking these observations into consideration it could be suggested, that substances acting solely on peripheral opioid receptors could be potent anti-pruritic or even anti-inflammatory drugs, but devoided of typical side effects related to the activation of central opioid system.
Export Options
About this article
Cite this article as:
Reich Adam and C. Szepietowski Jacek, Non-Analgesic Effects of Opioids: Peripheral Opioid Receptors as Promising Targets for Future Anti-Pruritic Therapies, Current Pharmaceutical Design 2012; 18 (37) . https://dx.doi.org/10.2174/138161212803582405
DOI https://dx.doi.org/10.2174/138161212803582405 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Advances in the Molecular Pathogenesis of Inflammatory Bowel Disease.
This thematic issue will emphasize the recent breakthroughs in the mechanisms of Inflammatory bowel disease (IBD) pathogenesis and devotes some understanding of both Crohn’s and ulcerative colitis. It is expected to include studies about cellular and genetic aspects, which help to precipitate the disease, and the immune system-gut microbiome relations ...read more
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Last Generation of Amino-Bisphosphonates (N-BPs) and Cancer Angiogenesis: A New Role for These Drugs?
Recent Patents on Anti-Cancer Drug Discovery MicroRNA Therapeutics: the Next Magic Bullet?
Mini-Reviews in Medicinal Chemistry Potential Beneficial Effects of Garlic in Oncohematology
Mini-Reviews in Medicinal Chemistry Localisation of Endothelin-1 and its Receptors in Vascular Tissue as Seen at the Electron Microscopic Level
Current Vascular Pharmacology Recent Advances in Anti-Survivin Treatments for Cancer
Current Medicinal Chemistry Dual-Specificity MAP Kinase Phosphatases as Targets of Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Roles of Laminin-332 and α6β4 Integrin in Tumor Progression
Mini-Reviews in Medicinal Chemistry Nuclear Factor-κB: A Holy Grail in Cancer Prevention and Therapy
Current Signal Transduction Therapy GLP-1 Agonists Exenatide and Liraglutide: A Review About Their Safety and Efficacy
Current Clinical Pharmacology Therapeutic Targets in Triple Negative Breast Cancer - Where are we now?
Recent Patents on Anti-Cancer Drug Discovery Melatonin as Antioxidant Under Pathological Processes
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Intracellular Bioinorganic Chemistry and Cross Talk Among Different -Omics
Current Topics in Medicinal Chemistry Generation of Redox Imbalance Mediates the Cytotoxic Effect of Malabaricone-A in a Multidrug Resistant Cell Line
Anti-Cancer Agents in Medicinal Chemistry Treatment Considerations to Overcome the Barriers Associated with Skin Cancer Targeting
Current Cancer Therapy Reviews Growth Hormone Secretagogue (Ghrelin-) Receptors - A Complex Drug Target for the Regulation of Body Weight
CNS & Neurological Disorders - Drug Targets Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Topical Dermatological Drug Delivery: Quo Vadis?
Current Drug Delivery Signal Transduction Pathways and Transcriptional Mechanisms as Targets for Prevention of Emergence of Multidrug Resistance in Human Cancer Cells
Current Drug Targets Xanthohumol, a Prenylated Chalcone Derived from Hops, Suppresses Cancer Cell Invasion through Inhibiting the Expression of CXCR4 Chemokine Receptor
Current Molecular Medicine The Protein-Protein Interaction-Mediated Inactivation of PTEN
Current Molecular Medicine